ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Newell, Fredrickson Question Ethics Of Laetrile Trials

July 22, 1977

State Cancer Incidence Report Published by NCI, CDC

November 22, 2002

AACI Backs Year 200 Goals, Secures Pledge From NCI that New Centers Won’t Be Added At Expense of Old

July 20, 1984

UPCI To Lead Clinical Trials Of Eli Lilly’s Oncology Agents.

July 6, 2001

Research Triangles Lands Plant Drug Contract Renewal

April 9, 1976

The First BRCA1 Test Hits The Market; Are Oncologists, Patients Ready?

January 26, 1996